BMC Endocr Disord

Lower BMI and early weight loss tied to better liraglutide outcomes

October 29, 2025

Study details: A retrospective cohort study analyzed 209 adults with T2DM treated with liraglutide (3.0 mg daily) at Chiang Mai University between 2017 and 2022. The goal was to identify predictors of clinically significant weight loss (≥5%) at 6 months. Logistic regression assessed demographic, clinical, and biochemical factors.

Results:

Only 27.3% achieved ≥5% weight loss at 6 months. Two independent predictors emerged:

• Lower baseline BMI (odds ratio [OR], 1.12 per 1 kg/m² decrease; p=0.036)
• Greater weight loss at 3 months (OR, 2.22; p<0.001)

Other factors, including age, sex, HbA1c, and lipid profile, weren't significant.

Clinical impact: Early response and baseline BMI can guide patient selection and treatment decisions. Monitoring weight change at 3 months may help identify responders, enabling personalized therapy and avoiding prolonged ineffective treatment.

Source:

Wangpattanamongkol P, Manosroi W. (2025, October 23). BMC Endocr Disord. Predictors of weight reduction effectiveness with liraglutide in diabetes mellitus type 2 patients: a retrospective cohort study. https://pubmed.ncbi.nlm.nih.gov/41131486/